Study of the microcirculation level in bone with osteoporosis and osteoporotic fractures during therapy with recombinant erythropoietin, rosuvastatin and their combinations
DOI:
https://doi.org/10.18413/2500-235X-2015-1-4-57-60Abstract
The experiment was carried out in female white Wistar rats. The effects of recombinant erythropoietin, rosuvastatin and their combination were investigated based on the blood supply to the bone after a modelled experimental osteoporosis. It was found that the studied drugs prevent decrease of bone microcirculation in cases of osteoporosis and in callus tissue in experimental osteoporotic fractures, positively influencing the course of reparative regeneration of bone tissue.
Keywords:
osteoporosis, osteoporotic fracture, microcirculation, endothelial dysfunction, recombinant erythropoietin, rosuvastatinReferences
Аврунин, А.С. Формирование остеопоротических сдвигов в структуре костной ткани (Костные органы, структура костной ткани и её ремоделирование, концепция патогенеза остеопороза, его диагностика и лечение) / А.С. Аврунин, Н.В. Корнилов, А.В. Суханов – СПб., 1998. – 68 с.
Руководство по остеопорозу / под ред. Л.И. Беневоленскои. – М. : БИНОМ. Лаборатория знании, 2003. – 524 с.
Миронов, С.П. Остеопороз как медико-социальная проблема / С.П. Миронов // Проблема остеопороза в травматологии и ортопедии : материалы III конф. с междунар. участием (14-15 фев. 2006 г., г. Москва). – М. : ЦИТО им. Н.Н. Приорова, 2006. – С. 4.
Брошусь, В.В. Оксид азота как регулятор защитных и гомеостатических реакции организма / В.В. Брошусь // Укр. ревматол. журн. – 2003. – № 4. – С. 3-11.
Gribkova I.V. Nitric Oxide Activates Ca2+ Activated Potassium Current in Rat Tail Artery Smooth Muscle Cells via cGMP-Dependent Mechanism / I.V. Gribkova, R. Shubert, V.N. Serebryakov // Kardiologiia. – 2002. – № 8. – С. 34-37.
Napoli, C. Nitric oxide and atherosclerosis / C. Napoli, L.J. Ignarro // Nitric Oxide. – 2001. – Vol. 5. – P. 88-97.
Endothelial dysfunction in patients with hypertensive disease / Martynov A.I., Avetyan N.G., Akatova E.V., etc. // Kardiologiia. – 2005. – Vol. 45, No 10. – С. 101-104.
Nebieridze, D.V. Microcirculation disturbances in arterial hypertension and possible methods for their correction / D.V. Nebieridze, E.V. Shilova, S.N. Tolpygina // Cardiovascular Therapy and Prevention. – 2004. – No 4. – С. 28-32.
Protective action of enalapril and losartan at experimental osteoporosis / O.S. Gudyrev, A.V. Faitelson, M.V. Pokrovskiy and et al.a // Kursk Scientific and Practical Bulletin "Man and his Health" – 2011. – № 2. – С. 9-14.
Comparative Assessment of Endothelium-Associated Correction of Experimental Osteoporosis with Resveratrol and Etoksidol / A.V. Faitel'son, G.M. Dubrovin, O.S. Gudyrin and et al. // Reporter of Traumatology and Orthopedics named Priorov. – 2012. – No 1. – С. 8-11.
Laufs U., La Fata V., Plutzky J., Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors // Circulation. – 1998. – No 97. – Р. 1129-1135.
Markov Kh. M. Oxidant stress and endothelial dysfunction / Kh. M. Markov // Pathological Physiology and Experimental Therapy. 2005. – No 4. – С. 5-9.
Buemi M., Cavallaro E., Floccari F. et al. Erythropoietin and the brain: from neurodevelopment to neuroprotection // Clinical Science. – 2002. – No 103. – Р. 275 – 282.
Anagnostou A., Liu Z., Steiner M. et al. Erythropoietin receptor mRNA expression in human endothelial cells // Proc Natl Acad Sci U S A. – 1994. – No 91. – Р. 3974-3978.
Ohneda O., Yanai N., Obinata M. Erythropoietin as a mitogen for fetal liver stromal cells which support erythropoiesis // Exp Cell Res. – 1993. – No 208. Р. 327-331.
Ogilvie M., Yu X., Nicolas-Metral V. et al. Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts. // J Biol Chem. – 2000. – No 275. Р. 39754 – 39761.
Smith K.J., Bleyer A.J., Little W.C., Sane D.C. The cardiovascular effects of erythropoietin // Cardiovasc Res. – 2003. – No 59(3). Р. 538-548.
Manolis A.S., Tzeis S., Triantafyllou K. et al. Erythropoietin in heart failure and other cardiovascular diseases: hematopoietic and pleiotropic effects // Curr Drug Targets Cardiovasc Haematol Disord. – 2005. No 5(5). – Р. 355-375.
Cai Z., Semenza G. L. Phosphatidylinositol-3-Kinase Signaling Is Required for Erythropoietin-Mediated Acute Protection Against Myocardial Ischemia // Reperfusion Injury Circulation. – 2004. – No 109. Р. 2050-2053.
Chong Z.Z., Kang J.Q., Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt and mitochondrial modulation of cysteine proteases // Circulation. – 2002. – No 106. – Р. 2973-2979.
The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals / Kureishi Y., Luo Z., Shiojima I. et al. // Nat. Med. – 2000. – V. 6. – Р. 1004-1008.
Русский
English
